KR20240137102A - 인터류킨-23 수용체의 펩티드 억제제 및 이의 약제학적 조성물 - Google Patents

인터류킨-23 수용체의 펩티드 억제제 및 이의 약제학적 조성물 Download PDF

Info

Publication number
KR20240137102A
KR20240137102A KR1020247029181A KR20247029181A KR20240137102A KR 20240137102 A KR20240137102 A KR 20240137102A KR 1020247029181 A KR1020247029181 A KR 1020247029181A KR 20247029181 A KR20247029181 A KR 20247029181A KR 20240137102 A KR20240137102 A KR 20240137102A
Authority
KR
South Korea
Prior art keywords
composition
amount
compound
formula
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247029181A
Other languages
English (en)
Korean (ko)
Inventor
제랄딘 브록스
데이비드 티. 브레슬린
클라라 안두익스 칸토
크리스토퍼 폴 데 도벨라레
길다스 데니아우
주스티노 디 프레토로
필리프 페르난데스
루치카 콜라코비치
나탈리 메르텐스
베티 롬스타인 페데르센
고팔 라잔
다준 썬
세잘 파텔
Original Assignee
얀센 파마슈티카 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔브이 filed Critical 얀센 파마슈티카 엔브이
Publication of KR20240137102A publication Critical patent/KR20240137102A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020247029181A 2022-02-01 2023-01-31 인터류킨-23 수용체의 펩티드 억제제 및 이의 약제학적 조성물 Pending KR20240137102A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263305631P 2022-02-01 2022-02-01
US63/305,631 2022-02-01
PCT/US2023/061651 WO2023150500A1 (en) 2022-02-01 2023-01-31 Peptide inhibitors of interleukin-23 receptor and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
KR20240137102A true KR20240137102A (ko) 2024-09-19

Family

ID=85556753

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247029181A Pending KR20240137102A (ko) 2022-02-01 2023-01-31 인터류킨-23 수용체의 펩티드 억제제 및 이의 약제학적 조성물

Country Status (13)

Country Link
EP (1) EP4472999A1 (https=)
JP (1) JP2025506374A (https=)
KR (1) KR20240137102A (https=)
CN (1) CN118829647A (https=)
AU (1) AU2023215245A1 (https=)
CA (1) CA3250172A1 (https=)
CL (1) CL2024002263A1 (https=)
IL (1) IL314629A (https=)
MX (1) MX2024009477A (https=)
PE (1) PE20241895A1 (https=)
TW (1) TW202342496A (https=)
UY (1) UY40135A (https=)
WO (1) WO2023150500A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322423A (en) 2023-01-31 2025-09-01 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of the interleukin-23 receptor
WO2025062347A1 (en) * 2023-09-21 2025-03-27 Janssen Pharmaceutica Nv Interleukin-23 receptor antagonist for use in the treatment of ulcerative colitis
WO2025151385A1 (en) * 2024-01-08 2025-07-17 Janssen Pharmaceutica Nv Peptide inhibitors of interleukin-23 receptor and uses thereof
WO2025163534A1 (en) * 2024-01-31 2025-08-07 Janssen Pharmaceutica Nv Crystal form of a peptide inhibitor of interleukin-23 receptor
WO2025243217A1 (en) * 2024-05-22 2025-11-27 Janssen Pharmaceutica Nv Crystal forms of peptide molecules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Also Published As

Publication number Publication date
TW202342496A (zh) 2023-11-01
UY40135A (es) 2023-08-31
IL314629A (en) 2024-09-01
CA3250172A1 (en) 2023-08-10
CN118829647A (zh) 2024-10-22
EP4472999A1 (en) 2024-12-11
CL2024002263A1 (es) 2025-02-07
MX2024009477A (es) 2024-11-08
PE20241895A1 (es) 2024-09-19
WO2023150500A1 (en) 2023-08-10
JP2025506374A (ja) 2025-03-11
AU2023215245A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
US11939361B2 (en) Compositions of peptide inhibitors of Interleukin-23 receptor
KR20240137102A (ko) 인터류킨-23 수용체의 펩티드 억제제 및 이의 약제학적 조성물
CN102036656A (zh) 含有蜡的缓释制剂
WO2008064202A2 (en) Modified-release formulations of calcium receptor-active compounds
KR102197465B1 (ko) 디메틸푸마르산염을 함유한 장용성 정제
JP2022545862A (ja) Ｇｌｐ－１ペプチドを含む錠剤を生成するためのプロセス
JP5778184B2 (ja) 上皮増殖因子の経口投与可能薬学的ペレット
EP3042654A1 (en) Modified release compositions of epalrestat or a derivative thereof and methods for using the same
KR20230002361A (ko) 카파 오피오이드 수용체 효능제의 올리고당 제형
KR101761983B1 (ko) 구강내 속붕해 필름 조성물 및 그 제조방법
JP2023145581A (ja) インターロイキン－２３受容体のペプチド阻害剤の組成物
HK40117634A (zh) 白介素-23受体的肽抑制剂及其药物组合物
KR20250139359A (ko) 인터류킨-23 수용체의 결정질 펩티드 억제제의 제조 방법
CN116669710A (zh) 白介素-23受体的肽抑制剂的组合物
KR102936624B1 (ko) 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제
JPH1045619A (ja) 成長ホルモン分泌促進ペプチド含有経口製剤
TW201924661A (zh) 含有非馬沙坦的固體分散體
HK40092077A (zh) 白介素-23受体的肽抑制剂的组合物
EA051796B1 (ru) Композиции пептидных ингибиторов рецептора интерлейкина-23
JP2025524357A (ja) 多数の顆粒
JP2026011867A (ja) 経口吸収用ヒアルロン酸誘導体医薬組成物
JP2022545822A (ja) チダミド医薬組成物、その調製方法及びその適用
HK1226662A1 (en) Modified release compositions of epalrestat or a derivative thereof and methods for using the same
JP2009526783A (ja) イミダゾリルアルキル−ピリジンの安定な投薬製剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000